brivanib alaninate + ixabepilone

This drug is a **combination of brivanib alaninate and ixabepilone**. - **Brivanib alaninate** is an orally active prodrug of brivanib, a small-molecule inhibitor that selectively targets **vascular endothelial growth factor receptor (VEGFR)** and **fibroblast growth factor receptor (FGFR)** tyrosine kinases, leading to inhibition of angiogenesis and tumor growth. - **Ixabepilone** is a semisynthetic epothilone B analog and acts as a **microtubule inhibitor**, stabilizing microtubules and thereby inhibiting mitosis and inducing apoptosis in cancer cells. It is used intravenously as a chemotherapy agent. Preclinical and early phase clinical evidence demonstrates **synergistic anti-tumor activity** of the combination in solid tumor models, with the combination delaying tumor growth more effectively than either drug alone[3]. Clinical trials have explored this combination in advanced or metastatic solid tumors[3]. Brivanib was developed by Bristol Myers Squibb, and ixabepilone by Bristol Myers Squibb as well[3][7][5].

Other names

brivanibbrivanib alaninateixabepiloneaza-epothilone B